Bardy Diagnostics (BardyDx) has announced today the appointment of Ed Vertatschitsch as chief operating officer. Effective 2 January 2020, the appointment will see Vertatschitsch responsible for leading all operations, research & development, and regulatory and quality affairs functions, the business said in a press statement.
The company is the developer of ambulatory cardiac monitoring technologies including its Carnation Ambulatory Monitor (CAM), a P-wave centric ambulatory cardiac patch monitoring and arrhythmia detection device.
“We are pleased to have Ed Vertatschitsch join BardyDx’s executive team,” said Gust Bardy, Bardy Diagnostics’ founder and chief executive officer. “Vertatschitsch brings a wealth of operational and development experience across the spectrum from early-stage to large-sized companies. We are thrilled to have him join our team as we continue to expand our product line and rapidly broaden our customer base.”
Prior to joining BardyDx, Vertatschitsch served as VP of Global Portfolio Solutions, VP of Treatment and Imaging Solutions–Delivery Systems, and general manager at Varian Medical Systems. Vertatschitsch joined Varian Medial Systems following the acquisition of Calypso Medical, where he was president and CEO. Previously, he also served as EVP Operations and R&D and VP of Engineering at Calypso Medical.
“BardyDx is experiencing accelerating growth with the success of the CAM patch and the development of novel ECG analysis technologies,” said Vertatschitsch. “It is an honour to join Dr Bardy and the innovative team at BardyDx, and I am excited and eager to help further the company’s success.”
BardyDx also announced further additions to its leadership team, including the appointment of Cristina Gutierrez as VP of Market Development & Training. She brings cardiac monitoring experience, BardyDx noted in its release, having formerly served as director of marketing at iRhythm Technologies. She possesses over 19 years of experience and has held senior marketing and sales positions at MedBridge, Athios Health, Velano Vascular, FoxHollow Technologies (acquired by ev3 and Covidien), and Cordis.
Additionally, Liz Mynhier has been promoted from senior director to VP of Clinical Services & Customer Experience. Mynhier has managed and grown BardyDx’s ECG monitoring center located in Houston, Texas. Prior to BardyDx, she served in the Cardiac Rhythm Management division at Medtronic and Biotronik.
Brit Baird has also been promoted from senior director to VP of Regulatory Affairs & Quality Assurance. BardyDx noted in its statement that he possesses over 23 years of experience with senior regulatory, quality, and manufacturing roles at EKOS Corporation (a BTG International group company), Pathway Medical Technologies (acquired by Bayer Healthcare), and Boston Scientific.
“I’m thrilled to welcome the newest additions to our Leadership Team,” said Mark Handfelt, chief administrative officer. “I have had the pleasure of working with Vertatschitsch in the past and look forward to working with him again. Our ability to recruit talented people from the outside, while providing opportunities for promotions and career progression within our organisation, is a testament to the strength of our products, our management team, and our investors.”